Bevacizumab biosimilar (Shanghai Institute Of Biological Products)

贝伐珠单抗生物类似药（上海生物制品研究所）

Report date: 2025/01/15 15:53:20

Base Information

Drug NameBevacizumab biosimilar (Shanghai Institute Of Biological Products)
Drug Alias NameBevacizumab biosimilar (Fudan-Zhangjiang)贝伐珠单抗生物类似药（复旦张江）Recombinant anti-VEGF humanized monoclonal antibody (Fudan-Zhangjiang)重组抗VEGF人源化单抗（复旦张江）生唯宁 +[6] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[6] 
Global Approved IndicationsUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[6] 
Approved Indications in ChinaUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[6] 
Original Approved Country/TerritoryMainland China
Original Approved Date2025/01/08
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShanghai Institute of Biological Products Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Institute of Biological Products Co Ltd
Inactive CompaniesShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Active IndicationsUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A